Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Trupanion

Having enough cash on hand during market sell-offs can allow investors to purchase both value and growth stocks at a bargain price. Here are two companies to consider.

Got $2,000 in Cash? Here Are the Top Healthcare Stocks to Buy Now

Bausch (BHC) misses on earnings and sales in the second quarter and announces plans to spin off its eye care division.

Bausch (BHC) Q2 Earnings & Revenues Miss Estimates, Down Y/Y

Bausch Health Companies Inc (BHC) CEO Joseph Papa on Q2 2020 Results - Earnings Call Transcript

Bausch's decision to carve out its eye care business into a stand-alone unit appears to be a hit with investors.

Why Bausch Health Companies Stock Is on Fire Today

Bausch Health Cos. shares BHC, +2.47% soared 27% in premarket trade Thursday, after the company said it is planning to spin off its eye-care business into a separate public company, confirming a Wall Street Journal report.

UPDATE: Bausch Health shares soar 27% premarket  after confirming to spin off eye-care business

Bausch Health Cos. shares BHC, +2.47% soared 23% in premarket trade Thursday, after a Wall Street Journal report that the company is planning to spin off its eye-care business from its core pharma operations, citing people familiar with the matter.

Bausch Health shares soar 23% premarket on report to spin off eye-care business

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Bausch Health (BHC) Might Surprise This Earnings Season

Bristol-Myers

Cooper Companies

Medtronic

Envista Holdings Corp

These 5 healthcare stocks look like the sector's best, with downside protection and room for price appreciation even if the market falters.

5 Healthcare Stocks for Good (Portfolio) Health

Bausch Health Cos. BHC, -3.07% will pay a $45 million fine to settle charges that the company misled investors in financial statements when it was known as Valeant Pharmaceuticals, according to the Securities and Exchange Commission late Friday.

Bausch Health to pay $45 million fine to settle Philidor charges

LAVAL, QC, July 31, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), f/k/a Valeant Pharmaceuticals International, Inc.

Bausch Health Resolves Legacy SEC Investigation

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bausch Health (BHC) Q2 Earnings Expected to Decline

LAVAL, QC, July 23, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") will release its second-quarter 2020 financial results on Thursday, Aug.

Bausch Health Companies Inc. Will Release Second-Quarter 2020 Financial Results On August 6

Gilead Sciences

Johnson & Johnson

Pfizer

Author Gerald Posner discusses his latest book, a history of the pharmaceutical industry.

Capital Interviews: Gerald Posner Discusses His New Book On Pharma, The Pandemic, And The Future Of The Industry

Bausch Health: Setting Its Sights On Eye Care

From 2015-2016, BHC lost roughly 90% of its stock value due to the Company’s destructive acquisition strategy—purchasing drugs and inflating their prices—which led to a highly leveraged business model.

Bausch Health: Investors Were Acknowledging The Turnaround Before COVID-19 Struck

Goldman Sachs

Bausch Health Companies Inc. (BHC) Management Presents at Goldman Sachs Fifth Annual Leveraged Finance Conference (Transcript)

Bausch Health Companies’ stock, formerly called Valeant Pharmaceuticals, and best known for its contact lenses and branded generic drugs, has declined by more than 35% this year, due to the impact of Covid-19 on its business.A Covid recession will impact the company’s revenues and cash flows.

Does Bausch Health Have Enough Cash For A Covid-19 Led Recession?

The Buy Case For Bausch Health

Comparing the trend in Bausch Health Companies’ stock, best known for its contact lenses and branded generic drugs, over recent months with its trajectory during and after the Great Recession of 2008, we believe that the stock can potentially gain 15% once fears surrounding the coronavirus.

What’s Next For Bausch Health Stock After 50% Rally?

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at Goldman Sachs Global Healthcare Conference Call (Transcript)

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Bausch (BHC) Up 21.2% Since Last Earnings Report: Can It Continue?

Bausch Health Companies, best known for its contact lenses and branded generic drugs, has seen its stock fall more than 35% year-to-date, as the coronavirus pandemic is expected to have a meaningful impact on its businesses. BHC stock also remains down by about 11% from levels seen in early 2018.

After 35% Decline Does Bausch Health Companies Stock Look Attractive?

Tivity Health

Investing in companies that are forced to write down their assets due to botched acquisitions can have devastating consequences for investors.

2 Healthcare Stocks At High Risk Of A Writedown

TransDigm

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

News for Bausch Health Companies Inc Stock (BHC)